Research Protocol

Tirzepatide 15mg — Research Protocol

Dosage Calculator → How to Reconstitute →

Tirzepatide — 15mg protocol. Edit the doses below for the 15mg vial.

Quickstart Highlights

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite[1][2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists[3][4].

  • Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.
  • Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
  • Easy measuring: At 7.5 mg/mL, 1 unit = 0.01 mL = 75 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

Dosing & Reconstitution Guide

Standard / Gradual Approach (2 mL = 7.5 mg/mL)

Phase Weekly Dose (mg) Units (per injection) (mL)
Weeks 1–4 2.5 mg 33 units (0.33 mL) × 1 injection
Weeks 5–8 5 mg 67 units (0.67 mL) × 1 injection
Weeks 9–12 7.5 mg 100 units (1.0 mL) × 1 injection
Weeks 13–16 10 mg 67 units (0.67 mL) × 2 injections

Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 28 days of reconstitution[6].

Supplies Needed

Plan based on an 8–16 week protocol with gradual titration (once‑weekly dosing).

  • Peptide Vials (Tirzepatide, 15 mg each):

     

    • 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 2 vials
    • 12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 4 vials
    • 16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 7 vials
  • Insulin Syringes (U‑100, 1 mL):

     

    • 8 weeks: 8 syringes (1/week)
    • 12 weeks: 12 syringes (1/week)
    • 16 weeks: 20 syringes (1/week wks 1–12, 2/week wks 13–16)
  • Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.

     

    • 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
    • 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.

     

    • Per week: 2 swabs (1 injection day)
    • 8 weeks: 16 swabs → recommend 1 × 100‑count box
    • 12 weeks: 24 swabs → recommend 1 × 100‑count box
    • 16 weeks: 32 swabs → recommend 1 × 100‑count box

Protocol Overview

Protocol Overview

Concise summary of the once‑weekly regimen.

  • Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation[2].
  • Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
  • Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.
  • Reconstitution: 2.0 mL per 15 mg vial (7.5 mg/mL) for manageable injection volumes.
  • Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.

Dosing Protocol

Suggested weekly titration approach.

  • Start: 2.5 mg once weekly for 4 weeks (initiation dose)[1].
  • Escalate: Increase by 2.5 mg every 4 weeks as tolerated.
  • Maintenance: 5–15 mg weekly based on response and tolerability.
  • Frequency: Once per week (subcutaneous), same day each week.
  • Timing: Any time of day; with or without food; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution[6].
  • Shelf life: Use reconstituted solution within 28 days[6].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

How It Works

Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors[1][2]. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation[2]. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials[3][4]. Its ~5‑day half‑life enables convenient once‑weekly administration[1].

Potential Benefits & Side Effects

Observations from clinical trials and published literature.

  • Glycemic control: Significant HbA1c reductions in type 2 diabetes trials[4][9].
  • Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses)[3][4].
  • Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies[9].
  • Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence[1][5].
  • Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
  • Prioritize protein to preserve lean mass during weight loss.
  • Combine resistance training and aerobic activity to support metabolic health.
  • Stay hydrated, especially given potential gastrointestinal effects.
  • Prioritize sleep and stress management to support adherence and recovery.

References

For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.